Showing results (151-160 of 760) with videos related to
Sort By:
Pageof 76
Future Oncology (London, England)|August 10, 2019
Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologicsKenneth C Anderson, Ola Landgren, Rebecca C Arend, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 14, 2007
Body mass index, physical activity, and risk of multiple myelomaBrenda M Birmann, Edward Giovannucci, Bernard Rosner, et al.Essays in Biochemistry|October 28, 2005
Proteasome inhibitors as therapeuticsConstantine S Mitsiades, Nicholas Mitsiades, Teru Hideshima, et al.Expert Review of Anticancer Therapy|July 9, 2005
Proteasome inhibition as a therapeutic strategy for hematologic malignanciesConstantine S Mitsiades, Nicholas Mitsiades, Teru Hideshima, et al.Biomaterials|August 12, 2025
Cancer vaccines: Discovery, development, and challenges for clinical translationZhongkun Zhang, Siyu Yao, Yufei Wang, et al.Journal of Controlled Release : Official Journal of the Controlled Release Society|July 22, 2025
Advances in RNA therapeutics and its delivery strategies against Multiple MyelomaKaiwen Luo, Zhongkun Zhang, Siyu Yao, et al.Leukemia|August 30, 2019
Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myelomaArghya Ray, Yan Song, Ting Du, et al.Hematology. American Society of Hematology. Education Program|November 26, 2002
Multiple myelomaKenneth C Anderson, John D Shaughnessy, Bart Barlogie, et al.Hematology/Oncology Clinics of North America|September 13, 2014
Novel targeted agents in the treatment of multiple myelomaCindy Varga, Jacob Laubach, Teru Hideshima, et al.Experimental Hematology & Oncology|July 21, 2017
Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target eraLi Zhang, Yu-Tzu Tai, Matthew Zhi Guang Ho, et al.Pageof 76